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Abstract
Anti-arrhythmic drug therapy is a frontline treatment for atrial fibrillation (AF), but its success
rates are highly variable. This is due to incomplete understanding of the mechanisms of
action of specific drugs on the atrial substrate at different stages of AF progression. We
aimed to elucidate the role of cellular, tissue and organ level atrial heterogeneities in the
generation of a re-entrant substrate during AF progression, and their modulation by the
acute action of selected anti-arrhythmic drugs. To explore the complex cell-to-organ mecha-
nisms, a detailed biophysical models of the entire 3D canine atria was developed. The
model incorporated atrial geometry and fibre orientation from high-resolution micro-com-
puted tomography, region-specific atrial cell electrophysiology and the effects of progressive
AF-induced remodelling. The actions of multi-channel class III anti-arrhythmic agents verna-
kalant and amiodarone were introduced in the model by inhibiting appropriate ionic channel
currents according to experimentally reported concentration-response relationships. AF
was initiated by applied ectopic pacing in the pulmonary veins, which led to the generation
of localized sustained re-entrant waves (rotors), followed by progressive wave breakdown
and rotor multiplication in both atria. The simulated AF scenarios were in agreement with
observations in canine models and patients. The 3D atrial simulations revealed that a re-
entrant substrate was typically provided by tissue regions of high heterogeneity of action
potential duration (APD). Amiodarone increased atrial APD and reduced APD heterogeneity
and was more effective in terminating AF than vernakalant, which increased both APD and
APD dispersion. In summary, the initiation and sustenance of rotors in AF is linked to atrial
APD heterogeneity and APD reduction due to progressive remodelling. Our results suggest
that anti-arrhythmic strategies that increase atrial APD without increasing its dispersion are
effective in terminating AF.
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Author Summary
The mechanisms behind the most common arrhythmia, atrial fibrillation (AF), remain
unclear and anti-arrhythmic drug therapy is often ineffective. In this paper, we develop
and apply a novel comprehensive 3D model of canine atria to investigate the role of atrial
heterogeneity in the mechanisms of AF and anti-arrhythmic drug action. We find that
regions of high heterogeneity of action potential duration (APD) throughout the atria typ-
ically provide substrate for arrhythmogenic re-entrant waves during both AF initiation
and progression. These mechanistic insights are directly linked with the efficacy of two
clinically used class III anti-arrhythmic drugs: amiodarone is more effective at terminating
AF than vernakalant, because it leads to an increase in atrial APD without increasing its
dispersion. Our computational results are consistent with clinical observations and can
help explain the superior efficacy of amiodarone in the clinical treatment of AF at late
stages. This framework can easily be extended to investigate the action of other anti-
arrhythmic drugs and translated to the human atria. By incorporating patient-specific
anatomical and electrophysiological information, and after undergoing careful validation,
the proposed in silico approach can become a useful tool to evaluate and potentially guide
anti-arrhythmic therapy in the clinic.
Introduction
Atrial fibrillation (AF) is the most common cardiac arrhythmia, imposing a large socio-eco-
nomic burden on society [1]. Currently, there are approximately 6 million adults in Europe
with AF and the number is expected to increase greatly [1]. AF is associated with high morbid-
ity and is often progressive, with electrical and structural remodelling of the atria leading to a
substrate that facilitates the self-perpetuation and resistance to treatment of the arrhythmia
[1]. The variety of mechanisms of AF onset and progression are incompletely understood [2],
which contributes the suboptimal success rates of clinical therapies [3]. Available anti-arrhyth-
mic drugs have major limitations, including poor long-term effectiveness and, for some, high
pro-arrhythmic risk [1,3].
Multiple studies have suggested that AF can be sustained by re-entrant waves propagating
in an abnormal atrial substrate [2,3]. However, mechanisms for the genesis of these waves dur-
ing AF remain unclear. Heterogeneous atrial tissue is more susceptible to re-entry leading to
conduction block in regions with gradients in refractoriness, high conduction anisotropy, or a
combination of these [4]. Experiments have provided evidence that channel blockers aimed at
producing anti-arrhythmic effects can instead result in re-entry linked with increased atrial
heterogeneity [5].
Moreover, the efficacy of drug therapy for AF is highly variable [1]. Amiodarone is known
for its superior efficacy in the clinical treatment of AF at all stages, whereas vernakalant is only
indicated for cardioversion of early-onset AF. The multi-channel blocking actions of amiodar-
one and vernakalant on action potentials (APs) are well-characterised in large animals, partic-
ularly the dog. However, mechanistic links between the drug action at the cellular level and the
resulting substrate changes at the organ level are unclear and not easily amenable to experi-
mental investigations.
Biophysical modelling has emerged as a powerful tool for dissecting the multi-scale mecha-
nisms of cardiac arrhythmia [6,7] and anti-arrhythmic drugs [8]. In the present study, we
developed a detailed biophysical model of 3D canine atria to integrate data from a single spe-
cies at the cell, tissue and whole atria levels, including multiple effects of remodelling. The dog
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has been extensively used in experimental AF studies and is arguably the only large species for
which information from the ionic channel to the organ level is available for comprehensive val-
idation of the model. We apply it to provide insights into the role of atrial heterogeneity in AF
generation and progression and to explore the acute action of amiodarone and vernakalant in
the atria in silico. We explore the hypothesis that the efficacy of these drugs is linked to their
effect on atrial heterogeneity, with the most effective drug actions leading to an overall increase
in refractoriness, without increasing its dispersion.
Methods
Atrial Single-Cell Models
The Ramirez-Nattel-Courtemanche (RNC) model for the right atrial (RA) cell [9] provides the
most widely used description for atrial canine single-cell electrophysiology. However, the
importance of the left atrium (LA) and the pulmonary veins (PVs) in AF and the emergence of
electrophysiological data from several atrial regions in the dog warrants the development of
novel models. Using RNC as the base model and integrating the latest experimental data exclu-
sively from the dog (S3 Table), single-cell models were created for four major atrial regions:
RA, LA, PV and Bachmann’s bundle-crista terminalis (BB-CT). The latter two bundles are spe-
cialised fast conduction tracts with electrophysiological properties distinctive from the RA, but
similar to one another [10,11].
Detailed experimental data [10,12–14] were used to update the formulations of major ionic
channel currents: ICaL and IK1 (Fig 1), Ito, IKur, IKr and IKs (S1–S4 Figs, respectively). A new
formulation for the time-dependent hyperpolarization-activated current, IKACh, which is con-
stitutively active in the dog [14], was included (S5 Fig). Intracellular calcium handling parame-
ters and regional ionic channel conductances were adjusted to reproduce experimental data
(Fig 2, S6 Fig, S1 and S2 Tables). Full details of the models and the complete set of equations
can be found in S1 Supporting Text.
Remodelling of ionic channel currents has been well characterised in experimental dog
models that develop AF in response to rapid atrial pacing (RAP) [15,16]. Hence, the relevant
ionic channel conductances were altered to model the remodelling process in the dog [16–19]
at two different stages: moderate (equivalent to 7 days of RAP) and advanced remodelling (42
days of RAP), as shown in Fig 2E and S4 Table. The same ionic remodelling factors were used
in all atrial regions [14].
Atrial Geometry and Fibre Orientation
The canine 3D atrial geometry was obtained through semi-automatic segmentation of 36-μm
resolution contrast-enhanced micro computed tomography (microCT) images (Fig 3A) [20].
Details concerning image acquisition and segmentation can be found in previous publications
[20,21]. For computational efficiency reasons the image resolution was reduced, producing a
computational grid with a spatial step of 300 μm.
Staining of the atria with an iodine solution (I2KI) prior to microCT imaging made myofi-
bres hyperintense in relation to surrounding connective tissue in the images [22]. The direc-
tion of the myofibres throughout the 3D atria was determined using structure tensor analysis
[23]. In short, the direction in which the image intensity changed the least was found by fol-
lowing the eigenvector corresponding to the lowest magnitude eigenvalue of the image’s struc-
ture tensor. The obtained direction of the myofibres throughout the 3D atria (Fig 3B) was
found to be in good agreement with published anatomical descriptions, as described in our
previous work [23].
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3D Biophysical Models
All electrophysiology simulations used the monodomain diffusion-reaction equation, as
detailed in the Supporting Text. Anisotropic electrical conduction was incorporated by setting
Fig 1. Electrophysiological properties of ionic channel currents in the canine atria. In created atrial
single cell models, the properties (lines) are validated against experimental data from the dog (symbols) [11].
a), b) L-type calcium current, ICaL: a) Steady-state values of the voltage-dependent activation (d) and
inactivation (f) variables as a function of membrane potential; b) Current-voltage relationship in the LA and PV
models. c) Inward rectifier current, IK1: Current-voltage relationships.
doi:10.1371/journal.pcbi.1005245.g001
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different diffusion coefficients for the directions parallel (Dlong) and perpendicular (Dtrans) to
the fibre orientation at each voxel (S5 Table). These were selected to ensure that simulated
atrial activation times (AT) and conduction velocities (CV) were in agreement with experi-
mental recordings from canine atria. Dlong and Dtrans were reduced by 33–50% in all regions of
the atria (“CV reduction” in S5 Table) to mimic the AF-induced structural and gap-junctional
remodelling of atrial tissue. We also considered another aspect of structural remodelling, addi-
tional to the overall reduction in CV: the increase of the conduction anisotropy ratio
(AR = Dlong/Dtrans) due to fibroblast proliferation and collagen deposition along atrial myofi-
bres [24] (“AR Increase” in S5 Table).
Re-entry was initiated in the 3D atrial model by fast pacing in the same site located in the
sleeves of the left superior PV (LSPV) using an S1-S2 protocol, with vulnerable windows com-
puted as described in the Supporting Text. We also characterised re-entrant activity by identi-
fying the number and localization of rotors (re-entrant circuits lasting over 200 ms), stable
rotors (lasting over 500 ms) and wavelets (broken activation wavefronts that do not meet the
criterion for a rotor) present in the 3D simulations.
Fig 2. Heterogeneous ionic channel and cellular properties in the canine atria. Created atrial single cell models
(bars) are validated against experimental data from the dog (symbols). a), b), c) Absolute values of the current densities
of three main ionic currents: Ito (at +20 mV), ICaL (+10 mV), IK1 (-100 mV). Dashed lines join data obtained in the same
experimental study. d) APD90 (1 Hz) for all regional models at different stages of ionic remodelling and the RNC model [9].
e) Multiplicative factors for each listed current for models of moderate and advanced ionic remodelling. Only ionic currents
that are remodelled with AF are shown. f) Blockade factors for amiodarone (A) at concentrations of 5 and 10 μM and
vernakalant (V) at 10 and 30 μM for each listed current. Only ionic currents that are affected by the considered drug
actions are shown. All sources of experimental data are summarised in S3 and S4 Tables.
doi:10.1371/journal.pcbi.1005245.g002
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Modelling Anti-Arrhythmic Drug Action
The actions of class III agents amiodarone and vernakalant were modelled as concentration-
dependent blockades of relevant ionic channel currents, in accordance with published dose-
response curves (Fig 2F, S8 Table). The actions of both drugs were modelled at two different
clinically-relevant concentrations also used in canine atrial studies [25]: 10 and 30 μM for ver-
nakalant; 5 and 10 μM for amiodarone. Drug administration was performed after 5 s of self-
sustained electrical activity associated with AF and was modelled as an instantaneous and per-
manent change in macroscopic conductances. In the absence of data on the effect of drugs on
Fig 3. High-resolution 3D canine atrial geometry and corresponding myofibre orientation. a) Posterior-superior view; b) Inferior-anterior view. The
atrial geometry was segmented into four major regions, which are described by the respective electrophysiological atrial cell models: RA (orange), LA (pink),
BB-CT (yellow) and PV (blue). Atrial fibres are coloured according to the local fibre orientation component along the anterior-posterior direction.
doi:10.1371/journal.pcbi.1005245.g003
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remodelled ionic channels, we made the explicit assumption that blockade factors were inde-
pendent of remodelling.
To gain insights into the mechanisms underlying drug action, we computed: single-cell val-
ues of AP duration at 90% repolarisation (APD90), 3D atrial APD90 and CV magnitude maps
and CV restitution curves and effective refractory periods (ERPs) as detailed in the Supporting
Text.
Results
Model Validation
The characteristics of the updated ionic channel currents, their heterogeneity and the changes
in APs caused by ionic remodelling were in excellent agreement with canine experimental data
(Fig 2A–2D and Fig 4). The AP morphologies for all four single-cell models were found to be
qualitatively similar to experimental AP recordings from the corresponding atrial regions, as
shown in Fig 4. Note that at the borders between tissue types, the APD gradients introduced
by the division of atrial tissue into regions with sharp boundaries are greatly smoothed by elec-
trotonic effects (S7 Fig).
Quantitatively, AP properties agreed well with those form experiments (Fig 2D): APD90 in
the BB-CT cell was the longest (201 ms at 2 Hz), followed by APD90 in the RA (166 ms), LA
(159 ms) and PV (120 ms). Drug-induced changes in APD90 were also in good agreement with
experimental data from canine atria (S11 Fig). Both APD90 values and APD90 dispersion were
reduced with increasing degrees of ionic remodelling (Fig 2D and Fig 4). Specifically, APD90 at
2 Hz decreases to 60–66% and 45–51% of the baseline values with moderate and advanced
ionic remodelling, respectively, in agreement with experimental findings from the dog [14,16].
The maximum upstroke velocity (dV/dtmax) was approximately 230 V/s in control conditions,
also in good agreement with experiments [25].
The choice of diffusion coefficients resulted in appropriate values of CV and AT in the 3D
atria, both in baseline and remodelling conditions, all in excellent agreement with canine data,
as shown in S6 and S7 Tables. Thus, simulated CV values were 0.94 and 1.18 m/s in the RA
wall and BB-CT bundles, respectively (S6 Table), which is in good agreement with respective
experimental data from the dog: 0.8–1.1 m/s in the atrial wall [18,26] and 1.0–1.3 m/s along
the BB bundle [27,28]. After remodelling-induced CV reduction (S6 Table), the longitudinal
CV in the RA wall was reduced to 0.64 m/s, again in agreement with experimental values of
0.6–0.9 cm/s measured in dogs after RAP [29,30].
Mechanisms of Arrhythmogenesis
The application of S1-S2 pacing in the LSPV of the 3D atria model produced arrhythmogenic
behaviour in several conditions associated with different stages of AF progression. Table 1
shows the computed vulnerable windows for conduction block and re-entry following such
pacing. Conduction block at the PV-LA junction was observed in all conditions, at increas-
ingly shorter values of S2 for higher degrees of ionic remodelling. Re-entry around the PVs, on
the other hand, was only observed in the presence of both ionic remodelling and CV reduc-
tion. An additional increase of AR (linked to fibrotic remodelling) did not considerably affect
the computed vulnerable windows. Nevertheless, the complexity of electrical activity increased
in these conditions, as additional re-entrant circuits at the RA-CT border quickly appeared,
both in moderate and strong ionic remodelling conditions.
Fig 5 shows snapshots of electrical activity in AF, simulated in the conditions of CV reduc-
tion and strong ionic remodelling (fixed rate pacing period, S1 = 100 ms; period of single extra
stimulus, S2 = 92 ms)–see S6 Video. Ectopic stimuli in the LSPV (Fig 5A) led to: conduction
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block (Fig 5B), the subsequent creation of two stable re-entrant circuits around the LSPV and
left inferior PV (Fig 5C) and, finally, wave breakdown leading to a secondary rotor in the LA
appendage (LAA). As APD was longer in the right side of the atria than in the left, excitation
wavefronts emanating from the PVs and spreading into the RA were eventually blocked at the
CT (Fig 5D). As a result, a stable rotor was formed in the RA, which was self-sustained and
independent of the LA (Fig 5E). Frequent collisions of the RA rotor with wavefronts emanat-
ing from the PVs/LA gave the electrical activity in the RA a complex appearance (Fig 5F). This
activity was sustained in both atria with a dominant frequency (DF) of 11 Hz for at least 10 s.
Fig 4. Heterogeneous APs in canine atrial cell models and their changes due to remodelling. a) APs (pacing frequency: 2 Hz) for baseline, moderate
and advanced ionic remodelling and equivalent canine experimental data when available (insets). b) APs for each of the atrial regional models (2 Hz), above
intracellular calcium transients (CaT) and each of the models’ currents in relative units. All sources of experimental data are summarised in S3 Table.
doi:10.1371/journal.pcbi.1005245.g004
Table 1. Vulnerable windows for conduction block and re-entry lasting at least 500 ms.
Conduction Block (ms)
Ionic Remodelling Baseline CV reduction AR increase
None 155–170 145–165 147–160
Moderate 107–120 85–105 97–117
Advanced 85–97 80–97 75–97
Re-Entry (ms)
Ionic Remodelling Baseline CV reduction AR increase
None − − −
Moderate − 93–97 102–105
Advanced − 80–90 92–95
Vulnerable windows change depending on different ionic and structural remodelling conditions.
doi:10.1371/journal.pcbi.1005245.t001
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With moderate ionic remodelling, a similar activation pattern was observed (S1 Video),
except that a stable rotor in the RA was not created. Conduction blocks still emerged due to a
combination of APD heterogeneity and anisotropy in the RA, leading to repeated collision of
wavelets. DF was 10 Hz in most regions, dropping to 6 Hz in RA regions where wavelet colli-
sions occur.
Intracellular Ca2+ dynamics can play an important role in AF mechanisms, primarily by ini-
tiating ectopic triggers for AF [2,3], but also by modulating local APD and ERP through Ca2+
overload. However, intracellular Ca2+ did not substantially affect rotor dynamics in the 3D
canine atrial simulations: only insignificant Ca2+ accumulation was observed (S8 Fig), in
agreement with experimental studies [31].
Anti-Arrhythmic Drug Action
In all four single-cell models, vernakalant increased the plateau potential and APD90 (S9 and
S10 Figs) [25,32]. Amiodarone, on the other hand, depressed the plateau (due to the blockade
of ICaL) and increased the duration of phase 3 (S9 and S10 Figs) [33]. Increasing concentrations
Fig 5. Generation and multiplication of re-entrant waves in the heterogeneous atria. All panels show an anterior-inferior view (left) and a posterior-
superior view (right) of the 3D voltage maps at indicated time points. Rotors are represented by black arrows and conduction block by white lines.
doi:10.1371/journal.pcbi.1005245.g005
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of vernakalant and amiodarone gave rise to increases in APD90, with 30 μM vernakalant
increasing APD90 the most (S9 Fig). Intrinsic interregional APD differences were, in general,
reduced by amiodarone and increased by vernakalant (part c of S9 Fig). These simulated drug
effects are in good agreement with available experimental data (S11 Fig). The action of both
drugs reduced dV/dtmax by 30–50% in a concentration-dependent manner [25,32] at the rates
associated with AF (6–10 Hz).
In the 3D atrial models, 10 μM amiodarone was very effective at reducing the complexity of
the observed electrical activity, eliminating most rotors (Table 2). At 5 μM, amiodarone was
less effective, with two rotors remaining in severe remodelling conditions and one stable rotor
emerging in the RA in moderate conditions. Vernakalant at all concentrations was in general
less effective than amiodarone, causing little change in the observed re-entrant pattern except
at high concentrations in advanced remodelling conditions, where two rotors were terminated
(Table 2).
Similar to observations made in single cell simulations (S9 Fig), APD90 in the 3D entire
atria was increased by both drugs as shown in Fig 6 (and DF were consequently decreased–see
Table 2). Fig 6 additionally shows that APD90 dispersion in the atria was substantially
increased by vernakalant, but reduced by amiodarone. These effects were not only interre-
gional (part c of S9 Fig), but also observed within distinctive atrial regions comprised of the
same tissue type (Fig 6A and 6B).
As with APD90, amiodarone reduced the dispersion of ERP across different tissue types,
whereas vernakalant increased it (Fig 7). The effect of drugs on APD90 and EPR dispersion
ultimately translates into the dispersion of the magnitude of CV (Fig 8). Due to a partial block-
ade of INa by both drugs (Fig 2D, S8 Table), the average CV was decreased throughout the 3D
atria (Fig 8). However, only vernakalant led to a higher occurrence of very slow CVs (Fig 8D)
and lines of conduction block (Fig 8C), which affected its ability to terminate AF (S13 Fig).
Discussion
In this study, an electrophysiologically and anatomically detailed model of the canine atria was
created and applied to explore the dynamics underlying AF in the entire atria. The model
revealed the basic mechanisms of AF development, from ectopic beats in PVs to rotors in
regions of high electrical heterogeneity and anisotropy: initially at the PV-LA junctions and, in
the advanced stages of AF, also at the RA-CT borders. The interaction of these rotors created
multiple wavelets and regions of conduction block, primarily in the RA. The genesis of AF in
the model is congruent with patterns seen in experimental and clinical studies [34,35]: a domi-
nant high-frequency "driver" in the PVs, increasingly complex activity in the RA and the
Table 2. Summary of the electrical activity observed after 5 s in 3D atria.
Ionic Remodelling Baseline Vernakalant 10 μM Vernakalant 30 μM Amiodarone 5 μM Amiodaron 10 μM
Moderate PV: 2 rotors;
RA: wavelets; 10.0 Hz
PV: 2 rotors;
RA: wavelets; 8.0 Hz
PV: 2 rotors;
RA: wavelets; 7.4 Hz
PV: 2 rotors;
RA: 1 rotor; 7.7 Hz
Only re-entry in CS
(S1 Video) (S2 Video) (S3 Video) (S4 Video) (S5 Video)
Advanced PV: 2 rotors;
LA: 1 rotor;
RA: 1 rotor, wavelets; 11.0 Hz
PV: 2 rotors;
LA: 1 rotor;
RA: 1 rotor, wavelets; 10.0 Hz
PV: 1 rotor;
RA: 1 rotor;
LA: 1 rotor; 8.3 Hz
PV: wavelets;
LA: 1 rotor;
RA: 1 rotor; 6.3 Hz
All activity terminated
(S6 Video) (S7 Video) (S8 Video) (S9 Video) (S10 Video)
Electrical activity is simulated at two ionic remodelling stages (including conditions of CV reduction), in baseline (drug-free) conditions and following the
application of anti-arrhythmic drugs. The mean dominant frequency in the LA is also shown for each situation when applicable. CS: coronary sinus.
doi:10.1371/journal.pcbi.1005245.t002
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emergence of a non-PV driver in chronic AF [34–37]. These are, for the first time, explained
by a unified framework that elucidates the mechanisms behind their genesis. Moreover, the
model was further applied to explore the acute action of two class III drugs and to propose an
explanation for their differential efficacy: actions that increase atrial APD90 without increasing
APD90 dispersion were more successful in terminating AF.
Biophysical Model Development
Atrial tachypacing in the dog has been extensively used as a model of AF, and applied to inves-
tigate its pathophysiological mechanisms, ranging from ionic remodelling [14,16,18] to the
relationship between AF and other comorbidities [2]. Furthermore, the effect of multiple anti-
arrhythmic drugs in AF has also been studied in detail using canine preparations [25,32,33].
Equally importantly, well-characterised canine atria have similar electrophysiology [9] and
Fig 6. Drug effects on APD90 heterogeneity in the 3D canine atrial model. a) Whole-atria APD90 maps,
measured after pacing the atria at 2 Hz from the sinoatrial node at baseline (B) and under the action of
amiodarone at 10 μM concentrations and vernakalant at 30 μM. b) Boxplots showing mean, standard
deviation and spread of APD90 measured in each of the major regions of the 3D atria. c) Histograms of APD90
across the entire atria.
doi:10.1371/journal.pcbi.1005245.g006
Fig 7. CV restitution curves and ERP calculated with 1D models for the PV and LA. Conditions of moderate (left)
and advanced (right) remodelling, at baseline (top) and under the action of 10 μM amiodarone (middle) and 30 μM
vernakalant (bottom panels) are shown. The numbers in each panel show ERP in ms (defined as the earliest BCL that
does not lead to conduction block) for each tissue type.
doi:10.1371/journal.pcbi.1005245.g007
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anatomy [38] to human atria. Therefore, it is reasonable to propose that an integrative bio-
physical model of the canine atria, validated by abundant cell-to-organ data from experimental
dog models, can improve the understanding of mechanisms of clinical AF and assist in evalu-
ating effects of anti-arrhythmic drugs.
Previous atrial modelling studies often use either 2D shells as geometric models of the atria
[39], or assume the 3D atrial myocardium is isotropic [39] or with an anisotropy assigned by
descriptive rules [40]. The current study utilises instead a highly-detailed anatomical model for
atrial geometry and myofibre orientation, which was created from a high-resolution contrast-
enhanced microCT dataset. As structural factors play an important role in wave dynamics
(S13 Fig), this model constitutes an important step towards accurately modelling abnormal
electrical activity in AF.
In the current study, a novel family of region-specific canine atrial cell models was also
developed and validated against experimental data at several levels (Figs 1 and 2, S1–S6 Figs).
The update of key ionic currents, such as ICaL and IK1, in the RNC model is crucial for simulat-
ing the drug action. The resulting models not only accurately reproduced electrical activity in
single cells, but also enable validated simulations the spatiotemporal dynamics in the 3D atria
Fig 8. Drug effects on CV heterogeneity in the 3D atria model. Whole-atria CV maps, measured after fast pacing from the LSPV at BCL = 150 ms in
moderate remodelling and CV reduction conditions a) at baseline; under the actions of: b) 10 μM amiodarone and c) 30 μM vernakalant. Patchy red
regions correspond to zones of decreased CV, which can also be seen in the corresponding histograms in panel d), as a slow-conduction left tail, which is
most prominent in the presence of vernakalant.
doi:10.1371/journal.pcbi.1005245.g008
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in sinus rhythm and AF. This is evidenced by the good agreement of the model with multiple
experimental measurements of CV and AT in healthy dogs (S6 and S7 Tables), as well as DF
[35,41] in both sinus rhythm and at various AF remodelling stages.
Genesis of Atrial Fibrillation
This study substantiates a link between re-entrant mechanisms sustaining AF and the underly-
ing heterogeneity and anisotropy of atrial tissue [4,21]. APD heterogeneity [4] and complex
myofibre arrangements [21] at the PV-LA junction were responsible for the initial conduction
block, which led to the formation of rotors when the wavelength was sufficiently reduced by a
combination of ionic remodelling and CV reduction. A similar combination of APD heteroge-
neity and anisotropy in the border of the RA-CT regions led to further wavebreaks in moder-
ate remodelling conditions and the formation of stable rotors in advanced remodelling (Fig 5).
Note that in advanced remodelling secondary rotors also appeared in the LA appendage via a
similar mechanism (Fig 5F).
These simulated scenarios of dominant rotors in the PVs and increasingly complex activa-
tions in the RA and LA match observations in canine RAP models [41] and clinical studies
[35] and are in qualitative agreement with several experimental findings: higher DFs in the LA
versus RA [35,41], increased DF with disease/RAP duration [35,41], as well as clinical observa-
tions of increasing formation of stable high-frequency sources away from the PVs in persistent
compared to paroxysmal AF patients [35].
Mechanisms of Drug Action
Insights into the role of electrical heterogeneity in AF provided by the 3D atrial model were
applied to explore the action of two anti-arrhythmic drugs. In the model, high-concentration
amiodarone was found to be more effective at terminating AF than vernakalant at any concen-
tration (Table 2), despite vernakalant’s superior ability to increase APD90 and ERP (Figs 6 and
7, S9–S11 Figs). An exception occurs in the CT-RA border where the administration of low-
concentration amiodarone led to a small local increase in APD90 heterogeneity (Fig 6A) and
ultimately to the stabilisation of wavelets into a rotor (Table 2). This can be linked to local high
anisotropy (S13 Fig), highlighting the difficulty of predicting drug action in realistic 3D atrial
geometries exclusively from single-cell models.
We propose that amiodarone’s high efficacy can be explained by the decrease in the disper-
sion of refractoriness (measured using either ADP90 or ERP) it induces in most regions (Figs 6
and 7). Vernakalant, on the other hand, increases electrical heterogeneity (Fig 6, S9 Fig), lead-
ing to CV dispersion and consequently conduction block (Fig 7) and wavebreaks (S13 Fig),
similar to a recent canine experimental study with a single-channel blockade [5]. Our findings
are in good agreement with amiodarone’s superior clinical effectiveness in the presence of AF
remodelling. They also agree with results from previous computational studies performed in a
1D strand using a human cell model, which showed amiodarone to be anti-arrhythmogenic
over a wide range of BCLs, for different drug concentrations and in the presence of remodel-
ling [42].
Amiodarone’s ability to reduce APD dispersion can be linked to its blocking effect on IK1
and ICaL (Fig 2F), the most heterogeneous currents across the different cell types. This is in
contrast to vernakalant, which mostly inhibits outward currents, particularly IKur, which do
not change across the atria. As vernakalant does not block ICaL, it increases APD to a much
greater extent than amiodarone–but it also increases heterogeneity. The studied drug actions
cannot however be attributed to the blockade of a single ionic channel. When we considered
amiodarone with the ability to block IK1 or ICaL removed, or vernakalant with the ability to
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block IK1 or ICaL added, the resulting effects on the CV restitution and ERP dispersion (S12
Fig) supported our initial hypothesis: the most effective drug actions increase ERP but reduce
ERP dispersion (S9 and S10 Tables). A similar effect has also been studied in human models of
AF, where it was found that regions where AF remodelling promoted a decrease in APD and
an increase in APD heterogeneity were most vulnerable to the initiation of re-entry [40].
Limitations
The presented model does not account for effects of patchy fibrosis [43] or autonomic innerva-
tion [44], which will be addressed in detail in future studies. We analysed a simpler condition
of increased tissue anisotropy, which can be linked to diffuse interstitial fibrosis. This is repre-
sentative of both dog models of AF and of 70% of AF patients who do not develop severe pat-
chy fibrosis [45,46]. This modelling approach also enables a separation of purely
electrophysiological effects from those related to the presence of patchy fibrosis. Additional
patchy fibrosis and vagal innervation can substantially increase electrical heterogeneity in the
atria [43,44], potentially contributing to AF through mechanisms similar to those described in
the current study.
The action of anti-arrhythmic drugs was modelled as a simple reduction of ionic channel
conductances, as is commonly done when modelling the action of class III drugs [8], not tak-
ing into account potential rate- and voltage-dependent blocking mechanisms [47]. Despite the
care taken in the present study, further detail may need to be included to model more accu-
rately the in vivo kinetics of these drugs. However, sufficient experimental data to create such
models are currently unavailable and the approach adopted here has effectively highlighted
distinctions between the combinations of conductances affected by amiodarone and
vernakalant.
Conclusion
This study demonstrates how in silico 3D atrial models can be created from highly detailed
ionic channel-to-organ electrophysiological and imaging data and applied to improve the
mechanistic understanding of arrhythmogenesis and anti-arrhythmic drug action in AF. The
model analyses scenarios of AF onset and progression in the whole atria, from rotor initiation
by ectopic beats in the PVs to the emergence of wave breaks and new rotors in both sides of
the atria at progressive stages of remodelling. These scenarios are congruent with multiple
experimental and clinical observations.
This study demonstrates the dominant role of cell-to-organ atrial heterogeneity in the initi-
ation and sustenance of rotors during AF and the success of anti-arrhythmic drug action in
terminating them. To the best of our knowledge, this is the first study where comprehensive
whole-atria in silico models have been successfully applied to provide a mechanistic link
between effects of specific class III drugs at the ionic channel level and the progressive re-
entrant substrate for AF in the entire atria.
Supporting Information
S1 Supporting Text. Detailed descriptions of canine single cell atrial models and 3D
whole-atria model.
(PDF)
S1 Fig. Electrophysiological characteristics of the transient outward current, Ito. a) Steady-
state values of the activation (oa) and inactivation (oi) variables as a function of membrane
potential. b) Time to peak (tpeak) and inactivation time constant (τinac) as a function of
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membrane potential. c) Peak current-voltage relationship. d) Normalised current as a function
of time for voltage steps of +50 and +10 mV (from -50 mV) as a function of time. (Experimen-
tal data for the LA cell taken from Ehrlich et al., 2003; Li et al., 2001.)
(PNG)
S2 Fig. Ultrarapid delayed rectifier current, IKur. Peak current-voltage relationship. (Experi-
mental data (for the LA and RA cells) is taken from Li et al., 2001.)
(PNG)
S3 Fig. Rapid delayed rectifier current, IKr. Peak current-voltage relationship. (Experimental
data (for the LA and RA cells) is taken from Li et al., 2001.)
(PNG)
S4 Fig. Slow delayed rectifier current, IKs. Peak current-voltage relationship. (Experimental
data for the LA and RA cells is taken from Ehrlich et al., 2003.)
(PNG)
S5 Fig. Time-dependent hyperpolarization-activated current, IKAch. a) Steady-state values
of the voltage-dependent activation variable (xa) as a function of membrane potential. b) Time
constant of the voltage-dependent activation (τxa) variable as a function of membrane poten-
tial. c) Peak current-voltage relationship. d) Normalised current in the LA model as a function
of time for voltage steps of -100, -40 and -20 mV (from -40 mV) as a function of time. (All
experimental data for both LA and PV cells is taken from Ehrlich et al., 2004.)
(PNG)
S6 Fig. Calcium Transient, CaT. CaT in the PV model at 1Hz and comparison with RNC
model and experimental data from Coutu et al., 2006.
(PNG)
S7 Fig. Effect of electrotonic loading on APD90 heterogeneity. APD90 was measured across
the LA-PV boundary in 3D (full blue line) and compared against single-cell APD90 values for
corresponding cell types (dashed black line). ERPs (measured in 3D) for each of the tissue
types are also shown (dark blue circles). Simulations were carried out at a BCL of 300 ms, with
moderate ionic remodelling and CV reduction conditions.
(PNG)
S8 Fig. Temporal evolution of the intracellular concentration of Ca2+ (Cai) in the 3D
model after fast pacing. Pacing was performed in the left superior PV, in conditions of CV
reduction and moderate ionic remodelling. Impulses are applied at 0 and 200 ms. The depolar-
izing wavefront (V> - 20mV) can be seen in red on the right hand side of each panel for the
same time points as the Cai maps on the left hand side. Time since initial pacing: a) 10 ms, b)
100 ms, c) 210 ms, d) 300 ms.
(PNG)
S9 Fig. Effect of anti-arrhythmic drugs on single cell action potentials. a) Action potentials
for the right atrium, paced at 2 Hz, in the absence of drugs and after administration of verna-
kalant or amiodarone for different degrees of ionic remodelling. b) Absolute APD90 values in
all cell types and c) differences in APD90 between right atrial tissues (BB-CT and RA) and left
atrial tissues (PV and LA) for: different degrees of remodelling (none, moderate or advanced)
at baseline (B) and after the application of either 5, 10 μM of amiodarone (A5, A10) or 10,
30 μM of vernakalant (V10, V30).
(PNG)
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S10 Fig. APD90 restitution curves. APD90 restitution curves in baseline (full line), moderate
(dashed line) and advanced (dotted line) ionic remodelling for all atrial cell types in baseline
conditions (top panel) and after the administration of 30 μM of vernakalant (centre panel) or
10 μM amiodarone (bottom panel).
(PNG)
S11 Fig. Relative changes in ERP and APD90 induced by drug administration. Experimental
data (black) is taken from Sicouri et al., 2012 for the action of vernakalant 30 μM on healthy
canine PVs and Sicouri et al., 2010 for the action of chronic amiodarone on healthy canine RA
cells. Simulations were carried out for the PV and LA cells using the described 1D cable model
(for ERP calculations) and single-cell models (for APD90) at a BCL of 500 ms in the absence of
any remodelling.
(PNG)
S12 Fig. Conduction velocity restitution curves. Conduction velocity restitution curves sim-
ulated in 1D for PV (red) and LA (blue) cells, in conditions of moderate (full lines) and severe
remodelling (dashed lines). Panels show CV restitution curves for baseline values (top), in the
presence of amiodarone 10 μM (a), second panel) and vernakalant 30 μM (b), second panel).
The bottom two panels depict CV restitution curves for single-ionic channel modifications of
amiodarone 10 μM (a)) or vernakalant 30 μM (b)).
(PNG)
S13 Fig. Atrial activation times (ATs) in the presence of drugs in the 3D canine model.
Superior-posterior view of the atria, showing ATs during AF (moderate ionic remodelling, CV
reduction conditions) at a) baseline and after the application of b) amiodarone 10 μM and c)
vernakalant 30 μM. Panel d) shows the 3D fibre orientation in the same geometry. The rotor
around the LSPV (arrow) is terminated near the PVs by amiodarone (dashed lines), whereas
vernakalant creates an additional conduction block at the CT (full line).
(PNG)
S1 Table. Conductances of the currents used in each regional model. The formulation of
these currents is also cell-type dependent—see the last chapter of S1 Supporting Text for
details.
(PDF)
S2 Table. Ca2+-handling variables in the proposed family of models and the RNC model.
Only parameters whose values differ in the two models are listed.
(PDF)
S3 Table. Literature references for the canine experimental data shown in Figs 1, 3 and 4 in
the manuscript.
(PDF)
S4 Table. Multiplicative factors for ionic remodelling of each current. These are shown in
conditions of moderate (7-days of RAP) and severe (42-days of RAP) remodelling, accompa-
nied by the relevant references.
(PDF)
S5 Table. Values for the longitudinal diffusion coefficient (Dlong) and anisotropy ratio
(AR) for each region of the atria. These are shown for three different stages of structural
remodelling: baseline, CV reduction and additional AR increase.
(PDF)
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S6 Table. Longitudinal conduction velocity values (CVlongitudinal) measured in the 3D atrial
model. Values from the current study computed at a BCL of 350 ms are shown alongside cor-
responding experimental values measured experimentally in dogs.
(PDF)
S7 Table. Activation times in different regions when pacing from the sinoatrial node at a
BCL of 350 ms. SVC: superior vena cava; RAA: right atrial appendage; IVC: inferior vena
cava; LBB: left portion of Bachmann’s bundle; LAA: left atrial appendage; RSPV: right superior
pulmonary vein; RIPV: right inferior pulmonary vein.
(PDF)
S8 Table. Blockade factors for amiodarone and vernakalant. The values used to model 5 and
10 μM amiodarone (Amio) and 10 and 30 μM vernakalant (Verna) are accompanied by IC50
values from the literature for each current affected by the drug. Corresponding literature refer-
ences are also shown.
(PDF)
S9 Table. Outcome of 3D simulations after the administration of modified drug actions.
Modified amiodarone 10 μM (Amio 10) and 30 μM vernakalant (Verna 30) drugs were applied
and their outcome is compared to baseline (no drug) conditions. All simulations lasted 5 s.
Blockade factors for additional IK1 and ICaL blocks were 0.60.
(PDF)
S10 Table. Relationship between the effective refractory period (ERP), its dispersion and
the outcome of 3D simulations in the presence of the analysed drug actions. We show the
changes in effective refractory period (ERP) and dispersion of ERP between the LA and PV
cells effected by the analysed drug actions (shown in S12 Fig), as well as the qualitative out-
come of 3D simulations (S9 Table) for the same drug actions.
(PDF)
S1 Video. Spatiotemporal dynamics of electrical activity in the 3D atria in baseline (no
drugs), CV reduction and moderate ionic remodelling conditions.
(MP4)
S2 Video. Spatiotemporal dynamics of electrical activity in the 3D atria after the adminis-
tration of vernakalant (10 μM), in CV reduction and moderate ionic remodelling condi-
tions.
(MP4)
S3 Video. Spatiotemporal dynamics of electrical activity in the 3D atria after the adminis-
tration of vernakalant (30 μM), in CV reduction and moderate ionic remodelling condi-
tions.
(MP4)
S4 Video. Spatiotemporal dynamics of electrical activity in the 3D atria after the adminis-
tration of amiodarone (5 μM), in CV reduction and moderate ionic remodelling condi-
tions.
(MP4)
S5 Video. Spatiotemporal dynamics of electrical activity in the 3D atria after the adminis-
tration of amiodarone (10 μM), in CV reduction and moderate ionic remodelling condi-
tions.
(MP4)
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S6 Video. Spatiotemporal dynamics of electrical activity in the 3D atria in baseline (no
drugs), CV reduction and advanced remodelling conditions.
(MP4)
S7 Video. Spatiotemporal dynamics of electrical activity in the 3D atria after the adminis-
tration of vernakalant (10 μM), in CV reduction and advanced remodelling conditions.
(MP4)
S8 Video. Spatiotemporal dynamics of electrical activity in the 3D atria after the adminis-
tration of vernakalant (30 μM), in CV reduction and advanced remodelling conditions.
(MP4)
S9 Video. Spatiotemporal dynamics of electrical activity in the 3D atria after the adminis-
tration of amiodarone (5 μM), in CV reduction and advanced remodelling conditions.
(MP4)
S10 Video. Spatiotemporal dynamics of electrical activity in the 3D atria after the adminis-
tration of amiodarone (10 μM), in CV reduction and advanced remodelling conditions.
(MP4)
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